Search for: "TEVA SALES " Results 1 - 20 of 487
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
15 Nov 2016, 7:18 am by Robert Kraft
The AP reports that Teva Pharmaceutical announced that it would cease sales of its migraine patch treatment Zecuity (sumatriptan iontophoretic transdermal system) due to reports from patients that it caused “burns and scars where it was applied. [read post]
26 Jun 2018, 8:17 am by Gene Quinn
Teva, decide AIA Secret Sales appeared first on IPWatchdog.com | Patents & Patent Law. [read post]
9 Dec 2018, 12:10 pm by Steve Brachmann
Teva: Does On-Sale Bar Capture Secret Sales appeared first on IPWatchdog.com | Patents & Patent Law. [read post]
3 Mar 2012, 9:45 am by Lawrence B. Ebert
Teva gets 35 percent of its profit from sales of Copaxone.Reuters had noted of sales of generics of Teva: Despite two major launches in the last quarter -- generic versions of schizophrenia treatment Zyprexa and cholesterol lowering drug Lipitor with Ranbaxy -- U.S. generic sales fell 5 percent in the quarter to $1.2 billion. [read post]
12 Jul 2008, 1:13 am
Generically referred as Glatiramer Acetate, Copaxone is an anti-sclerosis drug that had US sales of $ 1.1 billion last year. [read post]
2 Mar 2018, 5:18 am by Dennis Crouch
Teva Pharma (Supreme Court 2018) [Helsinn cert petition] Helsinn has now filed its much anticipated petition for writ of certiorari focusing on the question of how exactly the 2011 AIA changed the “on sale bar. [read post]
26 Jun 2018, 8:51 pm by Patent Docs
Teva Pharmaceuticals that its patents were invalid by application of the on-sale bar under 35 U.S.C. 102(b). [read post]
22 Jan 2019, 9:55 am by Gene Quinn
Teva, Secret Sale Qualifies as Prior Art Under the AIA appeared first on IPWatchdog.com | Patents & Patent Law. [read post]
14 Sep 2007, 2:50 pm
Famvir is a relatively minor product for Novartis, with about $200 million in annual U.S. sales. [read post]
24 Jul 2009, 1:31 am
As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.Annual sales of Ortho Tri-Cyclen ® Lo were approximately $400 million in the United States for the twelve months that ended March 31, 2009 based on IMS sales data.Teva is currently involved in patent litigation concerning this product in the U.S. [read post]
5 Oct 2016, 1:41 am by Lisa Ouellette
Teva, which argued that contrary to the district court's opinion and position taken by the USPTO, the America Invents Act (AIA) did not change the meaning of "on sale" and "public use" in 35 U.S.C. [read post]
24 Sep 2008, 5:00 am
The brand brought in $1.45 billion for AstraZeneca last year, while U.S. sales of Respules gained 20 percent from 2006. [read post]
25 Aug 2021, 4:00 am by Offit Kurman
Teva’s sales of its generic carvedilol product (generic equivalent to GSK’s Coreg®) induce infringement of GSK’s U.S. [read post]
17 Apr 2014, 12:49 pm by Lyle Denniston
  Until that happened, the filing said, the amount it proposed would “fully protect” the rivals “for many months of sales even under their most wildly optimistic projections. [read post]
11 Mar 2012, 8:16 pm by Reproductive Rights
(TEVA) sought to intervene in a lawsuit between the Center for Reproductive Rights and the U.S. government over emergency contraceptives, saying loosening sales... [read post]
16 Mar 2019, 8:51 pm by Patent Docs
Teva, and what does it mean for on-sale bars... [read post]
14 Sep 2021, 6:47 am by Erica Blachman Hitchings
  In addition, the court noted that an Associate Director in Teva’s Patient Services Department specifically warned that a reduction in the company’s donations would result in a decrease in sales. [read post]